References
- Jemal, A., Murray, T., Samuels, A., Ghafoor, A., Ward, E. and Thun, M.J. (2003) "Cancer statistics", CA Cancer J. Clin. 53, 5.
- Giles, F.J., Keating, A., Goldstone, A.H., Avivi, I., Willman, C.L. and Kantailian, H.M. (2002) "Acute myeloid leukemia", Hematology, 73, (Am. Soc. Hematol. Educ. Program).
- Carella, A.M., Berman, E., Maraone, M.P. and Ganzina, F. (1990) "Idarubicin in the treatment of acute leukemias. An overview of preclinical and clinical studies", Haematologica 75,159.
- Giles, F.J. (1998) "Monocyte-macrophages, granulocyte-macrophage colony-stimulating factor, and prolonged survi-val among patients with acute myeloid leukemia and stem cell transplants", Clin. Infect. Dis. 26, 1282.
- Slavin, M.A., Osborne, B., Adams, R., et al. (1995) "Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation—a prospective, randomized, double-blind study", J. Infect. Dis. 171, 1545.
- Marr, K.A., Seidel, K., Slavin, M.A., et al. (2000) "Prolonged fluconazole prophylaxis is associated with persistent protec-tion against candidiasis-related death in allogeneic marrow transplant recipients: long-term follow-up of a randomized, placebo-controlled trial", Blood 96, 2055.
- Winston, D.J., Chandrasekar, P.H., Lazarus, H.M., et al. (1993) "Fluconazole prophylaxis of fungal infections in patients with acute leukemia. Results of a randomized placebo-controlled, double-blind, multicenter trial", Ann. Intern. Med. 118, 495.
- Menichetti, F., Del Favero, A., Martino, P., et al. (1999) "Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo-controlled, double-blind, multicenter trial. GIMEMA Infection Program. Gruppo Italiano Malattie Ematologiche dell' Adulto", Clin. Infect. Dis. 28,250.
- Morgenstern, G.R., Prentice, A.G., Prentice, H.G., Ropner, J.E., Schey, S.A. and Warnock, D.W. (1999) "A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. U.K. Multicentre Antifungal Prophylaxis Study Group", Br. J. Haematol. 105, 901.
- Nucci, M., Biasoli, I., Akiti, T., et al. (2000) "A double-blind, randomized, placebo-controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients", Clin. Infect. Dis. 30, 300.
- Venkatakrishnan, K., von Moltke, L.L. and Greenblatt, D.J. (2000) "Effects of the antifungal agents on oxidative drug metabolism: clinical relevance", Clin. Pharmacokinet. 38, 111.
- Zuckerman, J.M. and Tunkel, A.R. (1994) "Itraconazole: a new triazole antifungal agent", Infect. Control Hosp. Epidemiol. 15, 397.
- Crespi, C.L., Miller, V.P. and Penman, B.W. (1997) "Microtiter plate assays for inhibition of human, drug-metabolizing cytochromes P450", Anal. Biochem. 248, 188.
- Stone, E.A., Fung, H.B. and Kirschenbaum, H.L. (2002) "Caspofungin: an echinocandin antifungal agent", Clin. Then 24, 351.
- Dresser, G.K., Spence, J.D. and Bailey, D.G. (2000) "Pharmacokinetic—pharmacodynamic consequences and clinical relevance of cytochrome P450 3A4 inhibition", Clin. Pharmacokinet. 38, 41.
- Buggia, I., Zecca, M., Alessandrino, E.P., et al. (1996) "Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo)", Anticancer Res. 16, 2083.
- Gillies, J., Hung, K.A., Fitzsimons, E. and Soutar, R. (1998) "Severe vincristine toxicity in combination with itracona-zole", Clin. Lab. Haematol. 20, 123.